Table 2.

Meta-analysis results for FD symptoms with regard to improvements with STW 5-II versus placebo

GIS item	After 28 days			After 56 days
	MD, 95% CI	p value	heterogeneity test p value (I2), %	MD, 95% CI	p value	heterogeneity test p value (I2), %
Epigastric pain	0.26 (0.10–0.42)	0.002*	0.001 (90)	0.3 (0.10–0.49)	0.003*	<0.001 (93)
Fullness	0.28 (0.10–0.46)	0.002*	0.006 (87)	0.29 (0.09–0.49)	0.005*	0.003 (89)
Early satiety	0.25 (0.06–0.45)	0.011*	0.121 (58)	0.26 (0.05–0.47)	0.014*	0.061 (72)
Nausea	0.11 (−0.10 to 0.31)	0.300	0.057 (72)	0.13 (−0.06 to 0.33)	0.185	<0.001 (93)
Vomiting	−0.23 (−0.53 to 0.06)	0.120	0.069 (70)	−0.24 (−0.56 to 0.09)	0.153	0.163 (49)
Abdominal cramps	0.22 (0.04–0.39)	0.013*	0.015 (83)	0.33 (0.15–0.51)	<0.001*	0.002 (90)
Acid eructation/heartburn	0.30 (0.10–0.50)	0.003*	0.027 (80)	0.34 (0.13–0.55)	0.002*	0.002 (89)
Sickness	0.20 (0.00–0.40)	0.047*	0.265 (20)	0.16 (−0.09–0.41)	0.202	0.119 (59)
Loss of appetite	0.23 (0.01–0.45)	0.038*	0.207 (37)	0.30 (0.05–0.54)	0.016*	0.198 (40)
Retrosternal discomfort	0.33 (0.14–0.52)	<0.001*	0.336 (0)	0.28 (0.05–0.52)	0.019*	0.065 (71)
Sum score	1.74 (0.90–2.58)	<0.001*	0.003 (88)	2.07 (1.09–3.04)	<0.001*	<0.001 (94)

CI, confidence interval; GIS, gastrointestinal symptom; I², i-square test; MD, mean difference.